Patrick G. LePore, a director at VYNE Therapeutics Inc. (NASDAQ:VYNE), recently acquired 15,000 shares of the company's common stock. The transaction, which took place on January 15, 2025 ...

VYNE Therapeutics (VYNE) announced positive results from the multiple ascending dose, MAD, portion of its Phase 1a SAD/MAD trial of VYN202. The Phase 1a trial was a two-part, double-blind ...

VYNE Therapeutics has completed enrollment for its Phase 2b trial of VYN201 gel, now named repibresib, for treating nonsegmental vitiligo, with top-line results expected in mid-2025. This clinical ...

TD Cowen analyst Stacy Ku maintained a Buy rating on VYNE Therapeutics (VYNE – Research Report) today and set a price target of $5.00. The ...

About VYNE Therapeutics Inc. VYNE is a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with ...

VYNE Therapeutics Inc., a Delaware-based pharmaceutical company specializing in immuno-inflammatory conditions, recently made key updates in its corporate presentation. On January 13, 2025 ...

US-based pharmaceutical company VYNE Therapeutics has completed enrolment in the randomised Phase IIb clinical trial of VYN201 gel, known as repibresib, for treating non-segmental vitiligo.

4 analysts have expressed a variety of opinions on VYNE Therapeutics (NASDAQ:VYNE) over the past quarter, offering a diverse set of opinions from bullish to bearish. The table below offers a ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Promising results support VYN202's potential as a novel, once-daily oral treatment for a broad range of immune-mediated disorders Consistent with Phase 1a SAD results, VYN202 demonstrated a ...

About VYNE Therapeutics Inc. VYNE is a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with ...